...
首页> 外文期刊>Chest: The Journal of Circulation, Respiration and Related Systems >Acute bronchodilator responsiveness in bronchiolitis obliterans syndrome following hematopoietic stem cell transplantation.
【24h】

Acute bronchodilator responsiveness in bronchiolitis obliterans syndrome following hematopoietic stem cell transplantation.

机译:造血干细胞移植后闭塞性细支气管炎综合征的急性支气管扩张药反应性。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: The obstructive abnormality of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (HSCT) is deemed to be virtually insensitive to treatment with inhaled bronchodilators. We studied whether nonconventional assessment of bronchodilation may help to detect physiologically meaningful airway responses missed by traditional criteria. METHODS: Standard spirometry, partial and maximal expiratory flow-volume curves, and lung volumes were measured before and 90 min after inhalation of albuterol plus tiotropium in 17 patients who developed mild to very severe BOS following HSCT. RESULTS: After treatment with bronchodilators, the standard criteria of reversibility based on FEV1 and FVC were met in seven out of 17 patients. In eight patients, residual volume (RV) decreased beyond its within-session spontaneous variability, and functional residual capacity (FRC) was reduced in four of them. Partial forced expiratory flow (Vpart) increased beyond its within-session spontaneous variability in nine patients. Out of 10 patients in whom neither FEV1 nor FVC met the standard criteria of reversibility, six had a positive increase in Vpart or a decrease of lung hyperinflation (ie, FRC) or RV. In six patients with limited expiratory flow during tidal breathing, the postbronchodilator increase in Vpart was correlated with a decrease in FRC (R2=0.83; P=.011). CONCLUSIONS: This study suggests that airway smooth muscle tone plays a significant role in BOS after HSCT and that the common knowledge of BOS as an irreversible obstructive disease may stem from the limitation of simple spirometry to detect changes in small airways. Trial registry: ClinicalTrials.gov; No.: NCT01112241 (BOS-01); URL: www.clinicaltrials.gov.
机译:背景:同种异体造血干细胞移植(HSCT)后的闭塞性细支气管炎综合征(BOS)阻塞性异常被认为对吸入性支气管扩张药的治疗不敏感。我们研究了非常规的支气管扩张评估是否有助于检测传统标准遗漏的生理上有意义的气道反应。方法:对17例HSCT后出现轻度至重度BOS的患者,在吸入沙丁胺醇和噻托溴铵之前和之后90分钟,测量标准肺活量,部分和最大呼气流量曲线以及肺活量。结果:用支气管扩张药治疗后,在17例患者中有7例符合基于FEV1和FVC的可逆性标准标准。在八名患者中,残余容量(RV)下降至其会话内自发变异性以上,其中四名患者的功能残余容量(FRC)降低。 9名患者的部分用力呼气流量(Vpart)增加至其会话内自发变异性。在FEV1和FVC均未达到可逆性标准标准的10例患者中,有6例的Vpart升高或肺过度充气(即FRC)或RV降低。在潮气呼吸中呼气流量受限的6例患者中,支气管扩张剂后Vpart的增加与FRC的减少相关(R2 = 0.83; P = .011)。结论:这项研究表明HSCT后气道平滑肌张力在BOS中起重要作用,而BOS作为不可逆性阻塞性疾病的常识可能源于简单的肺活量测定法检测小气道变化的局限性。试验注册表:ClinicalTrials.gov;编号:NCT01112241(BOS-01);网址:www.clinicaltrials.gov。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号